MAP2K7 and melanoma: To tackle this issue, we genetically affected the cellular HS decoration in human MV3 melanoma cells and investigated the cellular response to cytotoxic treatment with the MEK-inhibitor trametinib, the guideline-based drug in melanoma, or the DNA interfering agents doxorubicin and mitoxantrone, as relevant agents in melanoma therapy.